Cargando…

A Minimal Information Model for Potential Drug-Drug Interactions

Despite the significant health impacts of adverse events associated with drug-drug interactions, no standard models exist for managing and sharing evidence describing potential interactions between medications. Minimal information models have been used in other communities to establish community con...

Descripción completa

Detalles Bibliográficos
Autores principales: Hochheiser, Harry, Jing, Xia, Garcia, Elizabeth A., Ayvaz, Serkan, Sahay, Ratnesh, Dumontier, Michel, Banda, Juan M., Beyan, Oya, Brochhausen, Mathias, Draper, Evan, Habiel, Sam, Hassanzadeh, Oktie, Herrero-Zazo, Maria, Hocum, Brian, Horn, John, LeBaron, Brian, Malone, Daniel C., Nytrø, Øystein, Reese, Thomas, Romagnoli, Katrina, Schneider, Jodi, Zhang, Louisa (Yu), Boyce, Richard D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982727/
https://www.ncbi.nlm.nih.gov/pubmed/33762928
http://dx.doi.org/10.3389/fphar.2020.608068
Descripción
Sumario:Despite the significant health impacts of adverse events associated with drug-drug interactions, no standard models exist for managing and sharing evidence describing potential interactions between medications. Minimal information models have been used in other communities to establish community consensus around simple models capable of communicating useful information. This paper reports on a new minimal information model for describing potential drug-drug interactions. A task force of the Semantic Web in Health Care and Life Sciences Community Group of the World-Wide Web consortium engaged informaticians and drug-drug interaction experts in in-depth examination of recent literature and specific potential interactions. A consensus set of information items was identified, along with example descriptions of selected potential drug-drug interactions (PDDIs). User profiles and use cases were developed to demonstrate the applicability of the model. Ten core information items were identified: drugs involved, clinical consequences, seriousness, operational classification statement, recommended action, mechanism of interaction, contextual information/modifying factors, evidence about a suspected drug-drug interaction, frequency of exposure, and frequency of harm to exposed persons. Eight best practice recommendations suggest how PDDI knowledge artifact creators can best use the 10 information items when synthesizing drug interaction evidence into artifacts intended to aid clinicians. This model has been included in a proposed implementation guide developed by the HL7 Clinical Decision Support Workgroup and in PDDIs published in the CDS Connect repository. The complete description of the model can be found at https://w3id.org/hclscg/pddi.